Objective: To correlate chromosomal translocations of DUSP22 or TP63 with clinical significance in ALK-negative anaplastic large cell lymphoma (ALK(-)ALCL). Methods: Thirty-two patients with ALK(-)ALCL were selected from January 2004 to January 2014 at Fujian Provincial Hospital for the detection of chromosomal translocations of DUSP22 and TP63 by fluorescence in situ hybridization (FISH). The relationship between DUSP22 and TP63 chromosomal translocations and the clinicopathological parameters of ALK(-)ALCL was analyzed. Results: Among the 32 ALK(-)ALCL patients, 7(21.8%) had DUSP22 gene rearrangement (DUSP22(+)ALK(-)ALCL). Three patients (9.4%) had TP63 gene rearrangement (TP63(+) ALK(-)ALCL). There were 22 patients (68.8%) without rearrangement of either DUSP22 or TP63 (DUSP22(-)TP63(-)ALK(-)ALCL). The patients with DUSP22(+) ALK(-)ALCL were among the younger, and the patients with TP63(+) ALK(-)ALCL were among the elder. The mean age of patients with DUSP22(-)TP63(-)ALK(-) ALCL was between those of DUSP22(+)ALK(-)ALCL and TP63(+) ALK(-)ALCL (P<0.05). Based on Ann Arbor staging, incidence of DUSP22 gene rearrangement decreased as the clinical stage of ALK(-)ALCL increased (P<0.05). Incidence of TP63 gene rearrangement cases increases in patients at more advanced clinical stage(P<0.05). The five-year survival rate and prognosis of patients with DUSP22(+)ALK(-)ALCL were the highest. Patients with TP63(+) ALK(-)ALCL had the lower five-year survival and the worse prognosis (P<0.05). Conclusion: Presences of DUSP22 and TP63 chromosomal translocations correlate with the clinical stages and prognosis of ALK(-)ALCL and may be used for the differential diagnosis, determination of tumor aggressiveness and prognostication of ALK(-)ALCL.
目的： 探讨DUSP22、TP63在间变性淋巴瘤激酶（ALK）阴性的间变性大细胞淋巴瘤（ALK negative anaplastic large cell lymphoma，ALK(－)ALCL）中染色体易位与临床病理特征的关系。 方法： 选取福建省立医院病理科2004年1月至2014年1月32例ALK(－)ALCL患者存档蜡块中，应用荧光原位杂交（FISH）技术检测ALK(－)ALCL病例DUSP22、TP63染色体易位情况；统计分析DUSP22和TP63染色体易位与ALK(－)ALCL临床病理参数间的关系。 结果： 32例ALK(-)ALCL中，DUSP22基因重排（DUSP22(+) ALK(－)ALCL）患者7例（21.8%）；TP63基因重排（TP63(+) ALK(-)ALCL）患者3例（9.4%）；DUSP22基因和TP63基因均无重排的ALK(－)ALCL（DUSP22(-)TP63(-)ALK(-)ALCL）患者22例（68.8%）。DUSP22(+) ALK(－)ALCL患者较年轻（平均45岁），TP63(+) ALK(－)ALCL患者年龄更大（平均65岁）；DUSP22(-)TP63(-)ALK(-)ALCL患者年龄（平均56岁）介于DUSP22(+)ALK(－)ALCL患者和TP63(+)ALK(－)ALCL患者之间（P<0.05）。以Ann Arbor分期作为临床分期，DUSP22基因重排随ALK(－)ALCL临床分期的增加而减低（P<0.05）；TP63基因重排随ALK(－)ALCL临床分期的增加而升高（P<0.05）。DUSP22(+) ALK(－) ALCL患者5年生存率较高，预后可能更好；TP63(+) ALK(－)ALCL患者5年生存率较低，预后可能最差（P<0.05）。 结论： DUSP22和TP63相关染色体易位可能与ALK(－)ALCL临床分期以及预后有关，可以作为ALK(－)ALCL鉴别诊断以及判断ALK(－)ALCL恶性程度和预测预后的指标。.
Keywords: In situ hybridization, fluorescence; Lymphoma, T-cell; Lymphoma, large-cell, anaplastic.